| ￥3600 | |
| Z05685-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
>?95%?as?determined?by?Bis?Tris?PAGE > 95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized NKG2A&CD94 mFc Chimera, Human at 1 μg/ml (100μl/well) on the plate can bind Anti?NKG2A Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 56.9 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-90 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies. |
| Synonyms | CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
